Clinical trial
Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed…
NCT00266630 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00266630 |
|---|---|
| Title | Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder |
| Official title | Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Manic or Mixed Episode Associated With Bipolar I Disorder |
| Intervention type | Drug |
| Interventions | olanzapine, lithium, valproate, carbamazepine |
| Enrollment | 139 |
| Start date | Nov 1, 2005 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Dec 19, 2005 |
| Last update posted | Dec 28, 2010 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: